Pilot study demonstrates enhanced drug identification in SJS/TEN using granzyme assays, suggesting a safer assessment method.
The detection of GZB and Gr production in PBMC cultures provided a more sensitive and specific method than the conventional LTT for identifying culprit drugs in SJS/TEN. In particular, GZB detection at day 3 provided a shorter assay duration, avoided radioactive labeling, and demonstrated superior diagnostic performance. This cytokine-based approach may represent a practical and safer alternative to enhance drug causality assessment in patients with SCARs.
No takes yet. Share an insight, caveat, or question.
Srinoulprasert et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: